Platelet-rich plasma in ocular surface conditions: effects on visual acuity
Keywords:
Ocular surface, ocular surface diseases, persistent epithelial defect, blood derivatives, platelet-rich plasma, visual acuity, cornea.Abstract
Introduction: Autologous platelet-rich plasma has demonstrated the ability to accelerate healing and reduce visual function impairments in ocular surface diseases.
Objective: To evaluate best-corrected visual acuity in patients with ocular surface disorders treated with platelet-rich plasma as monotherapy.
Material and Methods: A pre-experimental before-after study was carried out on 111 patients with alterations of the ocular surface treated with autologous platelet-rich plasma eye drops in monotherapy in the Cornea service of the “Ramón Pando Ferrer” Cuban Institute of Ophthalmology, in the period between October 2021 and October 2022.
Results: Improvement in corrected vision was obtained in all patients treated with platelet-rich plasma (p=0.000) and particularly in post-corneal ulcer epithelial defects (p=0.000). The smallest difference between the final and initial best corrected visual acuity corresponded to patients with persistent epithelial defect (0.03, RI: 0.00-0.07) and the greatest difference to the corneal post-burn epithelial defect (0.50; RI: 0.30-1.34). Also, 96.4% of patients improved their corrected visual acuity, of which 49.5% reached <0.30 (logMAR).
Conclusions: It can be concluded that most patients with ocular surface conditions, once treated with PRP-A in monotherapy, have faster epithelialization and experience improvement in BCVA.Downloads
References
1. Schechter B, Mah F. Optimization of the Ocular Surface Through Treatment of Ocular Surface Disease Before Ophthalmic Surgery: A Narrative Review. Ophthalmol Ther [Internet]. 2022 [Citado 20/2/2024];11(3):1001-15. Disponible en: https://pubmed.ncbi.nlm.nih.gov/35486371/
2. Priyadarshini K, Sharma N, Kaur M, Titiyal JS. Cataract surgery in ocular surface disease. Indian J Ophthalmol [Internet]. 2023 [Citado 20/2/2024];71(4):1167-75. Disponible en: https://pubmed.ncbi.nlm.nih.gov/37026248/
3. León Rodríguez Y, Hernández Fernández Y, Pérez Parra Z, Moreno Ramírez M, Jareño Ochoa M. Plasma rico en plaquetas, regenerador en alteraciones corneales. Rev Cuba Oftalmol [Internet]. 2023 [Citado 20/2/2024];36(1). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_abstract&pid=S0864-21762023000100001&lng=es&nrm=iso&tlng=es
4. Wang EY, Kong X, Wolle M, Gasquet N, Ssekasanvu J, Mariotti SP, et al. Global Trends in Blindness and Vision Impairment Resulting from Corneal Opacity 1984-2020: A Meta-analysis. Ophthalmology [Internet]. 2023 [Citado 20/2/2024];130(8):863-71. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10355344/
5. GBD 2019 Blindness and Vision Impairment Collaborators, Vision Loss Expert Group of the Global Burden of Disease Study. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study. Lancet Glob Health. [Internet] 2021 [Citado 20/2/2024];9(2):e144-e160. Disponible en: https://pubmed.ncbi.nlm.nih.gov/33275949/
6. Tsubota K, Goto E, Shimmura S, Shimazaki J. Treatment of persistent corneal epithelial defect by autologous serum application. Ophthalmology [Internet]. 1999 [Citado 20/2/2024];106(10):1984-9. Disponible en: https://pubmed.ncbi.nlm.nih.gov/10519596/
7. Nuzzi A, Pozzo Giuffrida F, Luccarelli S, Nucci P. Corneal Epithelial Regeneration: Old and New Perspectives. Int J Mol Sci. [Internet] 2022 [Citado 20/2/2024];23(21):13114. Disponible en: https://pubmed.ncbi.nlm.nih.gov/36361918/
8. Zernii EY, Baksheeva VE, Yani EV, Philippov PP, Senin II. Therapeutic Proteins for Treatment of Corneal Epithelial Defects. Curr Med Chem [Internet]. 2019 [Citado 20/2/2024];26(3):517-45. Disponible en: https://pubmed.ncbi.nlm.nih.gov/28595546/
9. Anitua E. Plasma rich in growth factors: preliminary results of use in the preparation of future sites for implants. Int J Oral Maxillofac Implants [Internet]. 1999 [Citado 20/2/2024];14(4):529-35. Disponible en: https://pubmed.ncbi.nlm.nih.gov/10453668/
10. You J, Hodge C, Hoque M, Petsoglou C, Sutton G. Human Platelets and Derived Products in Treating Ocular Surface Diseases - A Systematic Review. Clin Ophthalmol Auckl NZ [Internet]. 2020 [Citado 20/2/2024];14:3195-210. Disponible en: https://pubmed.ncbi.nlm.nih.gov/33116370/
11. Gupta S, Paliczak A, Delgado D. Evidence-based indications of platelet-rich plasma therapy. Expert Rev Hematol [Internet]. 2021 [Citado 20/2/2024];14(1):97-108. Disponible en: https://pubmed.ncbi.nlm.nih.gov/33275468/
12. Nadelmann JB, Bunya VY, Ying GS, Hua P, Massaro-Giordano M. Effect of Autologous Platelet-Rich Plasma Drops in the Treatment of Ocular Surface Disease. Clin Ophthalmol Auckl NZ [Internet]. 2022 [Citado 20/2/2024];16:4207-13. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9762402/
13. Wróbel-Dudzińska D, Przekora A, Kazimierczak P, Ćwiklińska-Haszcz A, Kosior-Jarecka E, Żarnowski T. The Comparison between the Composition of 100% Autologous Serum and 100% Platelet-Rich Plasma Eye Drops and Their Impact on the Treatment Effectiveness of Dry Eye Disease in Primary Sjogren Syndrome. J Clin Med [Internet]. 2023 [Citado 20/2/2024];12(9):3126. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10179661/
14. Rodríguez YL, Parra ZP, Ramírez MEM, Fernández YH, Concepción YB. Aplicación del plasma rico en plaquetas en enfermedades de la superficie ocular. Rev Cuba Oftalmol [Internet]. 2021 [Citado 20/2/2024];34(3). Disponible en: https://revoftalmologia.sld.cu/index.php/oftalmologia/article/view/925
15. Vallvé C, Artés M, Cobo E, TREND group. [Non-randomized evaluation studies (TREND)]. Med Clin Barc [Internet]. 2005 [Citado 20/2/2024];125 Suppl 1:38-42. Disponible en: https://pubmed.ncbi.nlm.nih.gov/16464426/
16. UNESCO. La Declaración Universal de los Derechos Humanos | Naciones Unidas [Internet]. Paris: UNESCO; 1948 [Citado 12/07/2024]. Disponible en: https://www.sergas.es/Asistencia-sanitaria/Documents/599/146180S.pdf
17. The World Medical Association. Declaración de Helsinki de la AMM – Principios éticos para las investigaciones médicas en seres humanos [Internet]. Francia: The World Medical Association; 2024 [Citado 12/07/2024]. Disponible en: https://www.wma.net/es/policies-post/declaracion-de-helsinki-de-la-amm-principios-eticos-para-las-investigaciones-medicas-en-seres-humanos/
18. Council for International Organizations of Medical Sciences. International Ethical Guidelines for Health-Related Research Involving Humans [Internet]. Switzerland: Council for International Organizations of Medical Sciences; 2016 [Citado 12/07/2024]. Disponible en: http://www.cioms.ch
19. Panda A, Jain M, Vanathi M, Velpandian T, Khokhar S, Dada T. Topical autologous platelet-rich plasma eyedrops for acute corneal chemical injury. Cornea [Internet]. 2012 [Citado 20/2/2024];31(9):989-93. Disponible en: https://pubmed.ncbi.nlm.nih.gov/22759830/
20. Takayanagi Y, Kato S, Okada M. Benefits of autologous platelet tissue graft in wound healing after corneal refractive surgery: a case report. J Med Case Reports [Internet]. 2021 [Citado 20/2/2024];15(1):122. Disponible en: https://pubmed.ncbi.nlm.nih.gov/33722277/
21. García-Conca V, Abad-Collado M, Hueso-Abancens JR, Mengual-Verdú E, Piñero DP, Aguirre-Balsalobre F, et al. Efficacy and safety of treatment of hyposecretory dry eye with platelet-rich plasma. Acta Ophthalmol (Copenh) [Internet]. 2019 [Citado 20/2/2024];97(2):e170-e178. Disponible en: https://pubmed.ncbi.nlm.nih.gov/30450721/
22. Alio JL, Rodriguez AE, Ferreira-Oliveira R, Wróbel-Dudzińska D, Abdelghany AA. Treatment of Dry Eye Disease with Autologous Platelet-Rich Plasma: A Prospective, Interventional, Non-Randomized Study. Ophthalmol Ther [Internet]. 2017 [Citado 20/2/2024];6(2):285-93. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5693817/
Download PDF
